Drupal.behaviors.print = function(context) {window.print();window.close();}>
Study Supports Early Investigation of Infinity's PGx-Guided HSP90/mTOR Inhibitor Dual Attack Regimen
September 14, 2011
Study Supports Early Investigation of Infinity's PGx-Guided HSP90/mTOR Inhibitor Dual Attack Regimen
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Study Suggests Infinity's NSCLC Hsp90 Chaperone Inhibitor May Be Effective in Genetic Subpopulation
October 20, 2010 / Pharmacogenomics Reporter
Roche Receives FDA Nod for New PGx Indication for Tarceva in Metastatic NSCLC with Companion Dx
May 15, 2013 / Pharmacogenomics Reporter
FDA Approves Roche Test as CDx for Tarceva for Treating Certain NSCLC Patients
May 15, 2013 / GenomeWeb Daily News
PGx Drugs Xalkori, Zelboraf Show Strong Growth in First Quarter of 2013
May 1, 2013 / Pharmacogenomics Reporter
Biodesix Inks Deal with Bruker for Mass Spec Support; Closes on $8.8M in Series D Financing
April 11, 2013 / GenomeWeb Daily News